Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on targeted radiotherapeutics for central nervous system cancers, announced that Dr. Norman LaFrance will present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, at 1:00 p.m. ET. The panel will discuss 'Emerging Approaches to Radiotherapy: Plus Therapeutics & Y-mAbs Therapeutics.' Plus Therapeutics specializes in developing treatments for challenging conditions like recurrent glioblastoma and leptomeningeal metastases through innovative techniques combining image-guided local beta radiation and targeted drug delivery. The company has established a solid supply chain via strategic partnerships, ensuring the advancement and potential commercialization of its therapies.
Plus Therapeutics (PSTV) has advanced its clinical trial for rhenium (186Re) obisbemeda, targeting leptomeningeal metastases (LM), by completing Cohort 3 of the Phase 1/2a trial. The company expanded its clinical trial sites, adding Northwestern Memorial Hospital, which facilitates broader patient access. Notably, no dose-limiting toxicities were observed, indicating a promising safety profile. The FDA has already granted Fast Track designation for the treatment, highlighting its potential. The company expects to share complete Phase 1/Part A data by the second half of 2023, with a further meeting with the FDA planned to discuss next steps for Part B.
Plus Therapeutics, Inc. (PSTV) will announce its Q1 2023 financial results on April 20, 2023, after market close. Following this, the management team will host a conference call and webcast at 5:00 p.m. ET to discuss the results and provide a corporate update. Plus Therapeutics specializes in developing targeted radiotherapeutics for challenging cancers, utilizing a proprietary nanotechnology platform for enhanced drug delivery through liposomal encapsulation. More details about the event can be found on their investor relations website, along with a replay available for 90 days post-call.
Plus Therapeutics (PSTV) has successfully treated the first patient in Cohort 8 of its ReSPECT-GBM Phase 1/2a trial for rhenium (186Re) obisbemeda in recurrent glioblastoma. The trial has treated 25 patients without dose-limiting toxicities. Cohort 8 is now enrolling with a dose of 41.5 mCi, allowing treatment of larger tumors. The Phase 2 trial has treated five patients with a lower dose of 22.3 mCi. So far, safety and efficacy signals from the trials are promising, with no treatment-emergent toxicities noted. The FDA has granted Orphan Drug and Fast Track designations for this investigational therapy.
Plus Therapeutics (PSTV) has successfully initiated treatment of the first patient in Cohort 3 of its ReSPECT-LM Phase 1/2a clinical trial, aimed at treating leptomeningeal metastases from solid tumors. This follows the completion of previous cohorts without observing dose-limiting toxicities, with doses administered up to 26.4 millicuries. Encouraging safety and response data have been reported, showing significant reductions in cerebrospinal fluid tumor cell counts. The FDA has granted Fast Track designation for the therapy, supported by a $17.6 million grant from CPRIT. Preliminary results are expected to be presented in the latter half of 2023.
Plus Therapeutics announced the initiation of Phase 2 and Phase 1 trials for CNS cancers, focusing on rhenium (186Re) obisbemeda. The company secured a $17.6 million grant from the Cancer Prevention & Research Institute of Texas to support clinical development for leptomeningeal metastases. Their cash balance stood at $18.1 million as of December 31, 2022, sufficient to fund operations through 2025. The net loss for 2022 was $20.3 million, or $(0.77) per share. A conference call is scheduled for today to discuss financial results and future objectives, including expanding clinical trials and presenting safety data by the end of 2023.
Plus Therapeutics, Inc. (PSTV) has announced it will report its fourth quarter and full year 2022 financial results on February 23, 2023, after market close. Following the release, the management team will host a conference call and webcast at 5:00 p.m. ET to discuss the results and provide corporate updates. The company specializes in developing innovative radiotherapeutics for difficult-to-treat cancers, utilizing proprietary nanotechnology for improved drug delivery. A live webcast will be available and the replay can be accessed on their website for 90 days post-call.
Plus Therapeutics (PSTV) announced the completion of enrollment for Cohort 2 in the ReSPECT-LM Phase 1/2a clinical trial studying rhenium-186 obisbemeda for treating leptomeningeal metastases (LM). Anticipated data from Phase 1/Part A is expected in the second half of 2023. Initial results indicated that patients experienced a 46% to 92% reduction in cerebrospinal fluid tumor cell count post-treatment. The FDA has granted Fast Track designation for the therapy, supported by a $17.6 million grant from CPRIT. Next steps include a DSMB review and potential dose expansion discussions with the FDA.
Plus Therapeutics (PSTV) announced that the first patient has been dosed in the ReSPECT-GBM Phase 2b trial, evaluating rhenium (186Re) obisbemeda for recurrent glioblastoma (GBM). This multi-center trial aims to assess the safety and efficacy of direct tumor infusion using convection-enhanced delivery. Preliminary results from an earlier Phase 1/2a trial suggested a significant correlation between absorbed radiation dose and overall survival rates. The Phase 2b trial anticipates enrolling 31 patients over two years, supported by funding from the National Cancer Institute. The FDA has granted Orphan Drug and Fast Track designations for this innovative treatment.
Plus Therapeutics (PSTV) announced positive updates on its ReSPECT-GBM clinical trial of rhenium-186 obisbemeda for recurrent glioblastoma, showing safety and promising overall survival correlations with radiation doses. The Phase 2 trial enrollment has started, following a successful initial phase with no significant toxicities. Findings indicated a 35.7% reduction in death risk per 100 Gy dose increase. Additionally, the company is advancing into pediatric cancer trials, alongside updates on the ReSPECT-LM trial demonstrating good safety and efficacy in treating leptomeningeal metastases.